• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Hyderabad, July 13 Suven Life Sciences Ltd has applied to the Drug Controller-General of India (DCGI) for permission to undertake Phase-1 clinical trials with its investigational new drug SUVN-502, a novel, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HTs. According to a release, the drug was intended for the treatment of cognitive disorders such as Alzheimer’s and Schizophrenia. The company’s focus was on central nervous system disorders through novel mechanisms using small-molecule medical chemistry approaches, the release added. —

Our Bureau

More Stories on : Outlook | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Ranbaxy shuts down ‘unviable’ Pune formulations plant

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line